HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Strong humoral response elicited by a DNA vaccine targeting gastrin-releasing peptide with optimized adjuvants inhibits murine prostate carcinoma growth in vivo.

Abstract
Previous studies demonstrated that the elevated expression and receptor binding of gastrin-releasing peptide (GRP) in various types of cancer suggest that GRP might be a putative target for immunotherapy in neoplastic diseases. DNA vaccine for hormone/growth factor immune deprivation represents a feasible and attractive approach for cancer treatment; nevertheless, there is still a need to increase the potency of the DNA vaccine. Here, based on six copies of the B cell epitope GRP(18-27) in a linear alignment as an immunogen, we designed several anti-GRP DNA vaccines containing different combinations of immunoadjuvants, such as HSP65, tetanus toxoid(830-844) (T), pan HLA-DR-binding epitope (PADRE) (P), and mycobacterial HSP70(407-426) (M), on a backbone of pCR3.1 plasmid vector with eight 5'-GACGTT-3' CpG motifs and the VEGF183 signal peptide (VS). The effects of these immunoadjuvants in enhancing GRP-specific humoral immune response were then evaluated by comparing the respective immunogenicity and antitumor effects. Immunization of mice with pCR3.1-VS-HSP65-TP-GRP6-M2 elicited much higher levels of specific anti-GRP antibodies and more effectively inhibited the growth of a GRP-dependent tumor RM-1 in vivo. Interestingly, plasmids encoding for 2HSP70(407-426), but not the one with 1 or 3HSP70(407-426) showed stronger immune stimulatory potential as well as impressive antitumor activity, suggesting that 2HSP70(407-426) is an efficient molecular adjuvant for developing self-epitope vaccines. The highly immunogenic, potent anti-tumorigenic and antiangiogenesis activities of the anti-GRP DNA vaccine offered a novel immunotherapeutic approach in the treatment of GRP-dependent tumors and their complications.
AuthorsYong Lu, Didier J L Mekoo, Kedong Ouyang, Xiangbing Hu, Yanhua Liu, Ming Lin, Liang Jin, Rongyue Cao, Taiming Li, Yankai Zhang, Hao Fan, Jingjing Liu
JournalEndocrine-related cancer (Endocr Relat Cancer) Vol. 16 Issue 4 Pg. 1171-84 (Dec 2009) ISSN: 1479-6821 [Electronic] England
PMID19648182 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adjuvants, Immunologic
  • Cancer Vaccines
  • Heat-Shock Proteins
  • Malaria Vaccines
  • PADRE 45
  • Vaccines, DNA
  • Gastrin-Releasing Peptide
Topics
  • Adjuvants, Immunologic (genetics, therapeutic use)
  • Animals
  • Blotting, Western
  • Cancer Vaccines (genetics, therapeutic use)
  • Cell Proliferation
  • Chromatography, Affinity
  • Enzyme-Linked Immunosorbent Assay
  • Gastrin-Releasing Peptide (immunology)
  • Heat-Shock Proteins (genetics)
  • Immunity, Humoral
  • Immunization
  • Malaria Vaccines (genetics)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neovascularization, Pathologic
  • Prostatic Neoplasms (immunology, pathology, prevention & control)
  • Vaccines, DNA (genetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: